News Related to Early Onset Alzheimer Disease

Related coverage linked through entity extraction aliases.

Evidence review finds anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit

Apr 16, 2026

A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.

Canada's Drug Agency Recommends Against Public Coverage for Alzheimer's Drug Lecanemab

Mar 02, 2026

Canada's Drug Agency issued a draft recommendation against public drug plan coverage for lecanemab, an Alzheimer's treatment conditionally approved by Health Canada in October 2025, citing cost concerns despite the drug's ability to slow cognitive decline.